Strides Pharma Science

Strides Pharma Science Dividend Growth

The Year-over-Year Dividend Growth of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 60.00 %. In the previous year, Year-over-Year Dividend Growth was 66.67 % — a change of -10.00% (lower).

Dividend Growth

60.00 %

YoY

-10.00%

Last updated:

Year-over-Year Dividend Growth of Strides Pharma Science is 2025 60.00 % . Year-over-Year Dividend Growth of Strides Pharma Science was 2024 66.67 % . It decreases by -10.00% lower compared to the previous year.

The Strides Pharma Science Dividend Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Growth
Date
Dividend Growth
Jan 1, 2016
33.33 INR
Jan 1, 2017
12.50 INR
Jan 1, 2018
-55.56 INR
Jan 1, 2019
650.00 INR
Jan 1, 2020
-86.67 INR
Jan 1, 2021
25.00 INR
Jan 1, 2024
66.67 INR
Jan 1, 2025
60.00 INR
The Strides Pharma Science Dividend Growth history
YEARDividend GrowthYoY
60.00 %-10.00%
66.67 %+166.67%
25.00 %-128.85%
-86.67 %-113.33%
650.00 %-1,270.00%
-55.56 %-544.44%
12.50 %-62.50%
33.33 %-134.27%
-97.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Year-over-Year Dividend Growth of Strides Pharma Science is 60.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Dividend Growth Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Dividend growth measures the percentage increase in dividends compared to the previous year. Consistent dividend growth signals financial strength and shareholder commitment.

To evaluate Year-over-Year Dividend Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Dividend Growth.

Year-over-Year Dividend Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Dividend Growth's Strides Pharma Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Strides Pharma Science

All Key Metrics — Strides Pharma Science